Stock Market & Financial Investment News

News Breaks June 20, 2012 11:20 EDT PFE Pfizer committed to expanding recommendations for Prevnar 13 Pfizer confirmed that Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend the use of Pfizer’s Prevnar 13 for adults 19 years of age and older with immunocompromising conditions. The ACIP defines immunocompromised as those people who have functional or anatomic asplenia, HIV infection, cancer, advanced kidney disease, or other immunocompromising conditions. Pfizer said it is committed to continuing discussions with the ACIP with the aim of expanding the recommendations to include all adults 50 years of age and older. Pfizer is conducting a variety of clinical studies using Prevnar 13 in immunocompromised individuals and expects results at the end of 2012 and into 2013. Data on the safety and effectiveness of Prevnar 13 when administered to immunocompromised individuals are not available. Pfizer is conducting the Community-Acquired Pneumonia Immunization Trial in Adults and will share results with the ACIP once complete. Pfizer estimates that the primary outcome measures for this event-driven study will be available in 2013. News For PFE From The Last 14 Days Check below for free stories on PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 09:38 EDT PFE Active equity option families trading on open Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM June 17, 2013 16:00 EDT PFE Options Update; June 17, 2013 Subscribe for More Information 08:36 EDT PFE InSite Vision to join Merck, Pfizer patent suit against Mylan InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. 07:28 EDT PFE Cambridge Healthtech Institute to host a conference Subscribe for More Information June 14, 2013 16:00 EDT PFE Options Update; June 14, 2013 Subscribe for More Information 06:45 EDT PFE Zoetis volatility elevated into Pfizer split-off Subscribe for More Information June 13, 2013 16:00 EDT PFE Options Update; June 13, 2013 Subscribe for More Information 07:32 EDT PFE European League Against Rheumatism to host annual meeting Subscribe for More Information June 12, 2013 16:02 EDT PFE Options Update; June 12, 2013 Subscribe for More Information 13:31 EDT PFE Mylan could be interested in generic assets split from Pfizer, Bloomberg says 08:28 EDT PFE Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix Subscribe for More Information 08:02 EDT PFE Pfizer wins $2.15B settlement from Teva and Sun for patent infringement Subscribe for More Information June 11, 2013 16:00 EDT PFE Options Update; June 11, 2013 Subscribe for More Information 15:15 EDT PFE Pfizer June volatility at one-year high Subscribe for More Information 07:42 EDT PFE Boston Biotech Conferences to host a conference Subscribe for More Information June 10, 2013 07:40 EDT PFE Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information 07:20 EDT PFE Biomed to host a conference Subscribe for More Information June 4, 2013 07:28 EDT PFE Cambridge Healthtech Institute to host a conference Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.